Breast Cancer

The PAM50 risk of recurrence score can improve the prediction of recurrence at 10 years in postmenopausal patients with HR-positive early breast cancer.

Adding palbociclib to letrozole offers similar health-related quality of life and better pain scores in postmenopausal women with estrogen receptor–positive/HER2-negative metastatic breast cancer, compared to letrozole alone, according to an analysis of the PALOMA-2 trial.

No difference was found in pathologic complete response rates between neoadjuvant paclitaxel and nab-paclitaxel in women with ERBB2/HER2-negative breast cancer.

Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.

A new analytical tool called topographic single-cell sequencing can reveal a direct genomic lineage between in situ and invasive tumor subpopulations, which may help decipher how and why some DCIS become invasive.

Continuing letrozole therapy after 5 years of aromatase inhibitor therapy did not worsen quality-of-life measures in patients with HR-positive breast cancer.

This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

This video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.

The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.

This video highlights recent studies advancing the field of breast cancer screening and diagnosis, including the potential need for increased surveillance in patients with false positives and patient access to mammography.

After undergoing treatment, women with young-onset breast cancer and BRCA mutations had similar survival rates as those women who were not mutation carriers, according to the results of a prospective study.

This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.

This video highlights a study on optoacoustic imaging, a new type of imaging that could improve breast cancer diagnosis by differentiating between benign and malignant breast masses.

This video highlights results of REACT, a phase III multi-center double-blind randomized trial of celecoxib vs placebo in patients with breast cancer.

This video reviews studies investigating the use of germline clinical testing for breast cancer.

This video highlights quality-of-life results from a large prospective study of men treated for breast cancer.

Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2+, HR+ metastatic breast cancer.

Toxicities from buparlisib make it a poor option for patients with HR-positive, HER2-negative advanced breast cancer who progressed on mTOR inhibitor therapy.

Cardiac effects of pertuzumab and trastuzumab following chemotherapy in the neoadjuvant setting were limited for HER2-positive breast cancer patients.

A recent analysis from the Breast Cancer Surveillance Consortium revealed that community oncology practices are neglecting to use MRI screening for at-risk women, and lower-risk women are being unnecessarily screened.

In this slide show we highlight some of the top news on breast cancer in 2017, including long-term benefits of mammography, treatment advances, pregnancy in survivors, and more.

Undergoing axillary lymph node dissection is associated with increased arm morbidity in younger breast cancer patients compared with sentinel lymph node biopsy.

The PARP inhibitor talazoparib significantly increased progression-free survival over physician’s choice of therapy in a randomized phase III trial of patients with advanced breast cancer and a germline BRCA mutation.

This interview provides perspective on developments in breast cancer treatment in 2017, as well as a preview of what we can expect to change in the treatment of breast cancer in 2018.

Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 1 year of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer.